Citius Pharmaceuticals, Inc. (CTXR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Citius Pharmaceuticals, Inc. (CTXR) closed at USD 0.47 on 2026-10-14, a change of -70 % over the past year, with a market capitalization of USD 12.63M.

Citius Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Citius Pharmaceuticals, Inc. key figures

Previous close

USD 0.47 (2026-10-14)

1-year change

-70 %

Market cap

USD 12.63M

Enterprise value

USD 12.09M

P/E ratio (trailing)

-0.27

P/E ratio (forward)

-0.32

EPS (trailing)

-1.69

EPS (forward)

-1.44

PEG ratio

n/a

Price to book

0.19

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

28.14

Employees

23

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Citius Pharmaceuticals, Inc. and compare it with other stocks.